CVS 2018 Formulary: Outcomes-Based Contracts In Oncology, Obesity, COPD
Executive Summary
And for diabetes, Jardiance is out and Invokana is in; CVS formulary update includes far fewer exclusions than previous years and reinstates coverage for several drugs, signaling more muted approach to management.
You may also be interested in...
Prime Therapeutics Expanding Formulary Exclusion Program In 2018
The NetResults formulary contributed to a 0.2% decline in overall drug spending by the pharmacy benefit manager's commercial clients in 2017, according to Prime Therapeutics' Drug Trend report.
Large Employers Exploring Value-Based Contracting For Specialty Drugs
National Business Group on Health annual survey of employer-sponsored insurance finds continued concerns with specialty drug costs, growing interest in using accountable care organizations to control costs.
Policy Prescriptions: User Fees, EMA Worries, PBM Strategies, PRIME Milestones
The US has plenty of new pharma legislation, Europe has plenty of worries about EMA's Brexit move, pharmacy benefit managers give plenty more scrutiny to which products earn a place on formulary. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet.